USP-1

  • Mechanism

  • Disease areas

    Cancer

In the first quarter of 2020 Medivir entered into a licensing agreement with the US-based biotech company Tango Therapeutics for USP-1, one of Medivir’s preclinical research programs. Tango has announced that it expects to open an IND for a USP1-inhibitor in 2023. Through the agreement, Medivir is entitled to multiple development and commercial milestone payments as well as royalties on future sales.